Entries by Thomas Gabrielczyk

Opportunity Health SL wins start-up pitch contest

Out of 43 pitches, the founders of Spanish Opportunity Health S.L. delivered the best presentation for a new life sciences product: a choking device that can potentially be used by anyone in emergency situations without the need for external assistance.

Panel discussion: what drives US investments?

Alongside a start-up pitch featuring 45 international participants, the second day of BioSpain 2025 (7–9 October 2025, Barcelona) offered biotech start-ups a panel discussion with prominent US investors, who shared their selection criteria and outlined the impact of the current geopolitical situation on investment decisions.

Biomanufacturing in Switzerland

Switzerland is a key hub for biomanufacturing, with immunological products like antibodies
and vaccines making up 18.5% of 2024 exports. Swiss companies drive biotech innovation and biocatalysis
across sectors globally, extending the traditional focus on pharmaceuticals to fine chemicals, fragrances
and food tech. The development is supported by national collaborations and international coalitions.

Spain again tops Europe in clinical trials

Spain has once again secured the top position in Europe for clinical trials. According to various Clinical Research Organisations at BioSpain 2025 (7–9 October, Barcelona), this is largely due to the speed with which the Spanish Medicines Agency (AEMPS) approves clinical studies.

BioSpain 2025 starts with new records

BioSpain 2025 opened in Barcelona, the capital of Catalonia, setting a new record for both visitors and exhibitors. During the inauguration, representatives from government and industry highlighted the leading role of biotechnology in building economic and environmental resilience in Spain and across the European Union.

FDA approves atezolizumab–lurbinectedin for ES-SCLC

The U.S. FDA has approved atezolizumab and atezolizumab with hyaluronidase in combination with lurbinectedin as the first and only first-line maintenance therapy for adults with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after induction therapy with atezolizumab, carboplatin and etoposide.

Pharma Tariffs: US Government backtracks

After the surprising announcement of a 100% tariff on all prescription drugs imported into the United States, the US government appears to be backtracking. Within a few days, its trade policy stance towards the pharmaceutical industry has shifted fundamentally.

Biologics CDMO Rezon Bio leaves stealth mode

Rezon Bio has launched as a European contract development and manufacturing organisation (CDMO) for biologics. The new company has been created following the demerger of Polpharma Biologics into two independent companies.